Exhibit 99.1 Adverum Biotechnologies Reports First Quarter 2024 Financial Results and Provides Pipeline Highlights - Phase 2 LUNA interim analysis to be presented at ASRS Annual Scientific Meeting on July 17th, 2024 in Stockholm, Sweden - - $193.3 million in cash, cash equivalents and short-term investments expected to fund operations into late 2025 - REDWOOD CITY, Calif., May 9, 2024 - Adverum Biotechnologies, Inc. (Nasdaq: ADVM), a clinical-stage company pioneering the use of gene therapy as a new standar ...